Journal of Clinical Apheresis

Retrospective analysis comparing complication rates of centrifuge vs membrane-based therapeutic plasma exchange in the pediatric population 2022

Trends in the use of therapeutic plasma exchange in multiple myeloma.  35:307-315. 2020

Exclusive use of PowerFlow ports may not be appropriate for all patients.  35:66-68. 2020

New subcutaneous PowerFlow port results in cost and time-savings in a busy outpatient apheresis clinic.  34:482-486. 2019

Solving the calcium gluconate shortage in real-time: Mistakes made and lessons learned.  34:490-494. 2019

Debunking superstition: Analyzing the cloud phenomenon in apheresis—Results of a 35-month study.  33:616-618. 2018

Do we have enough evidence for recommending therapeutic plasma exchange for patients with natalizumab-associated progressive multifocal leukoencephalopathy?.  33:452-453. 2018

Plasma exchange for the management of refractory pruritus of cholestasis: A report of three cases and review of literature.  33:412-418. 2018

Therapeutic plasma exchange For Hashimoto's encephalopathy.  33:444-446. 2018

Hospital-acquired anemia due to diagnostic and therapy-related blood loss in inpatients with myasthenia gravis receiving therapeutic plasma exchange.  33:14-20. 2018

Increased troponin I is associated with fatal outcome in acquired thrombotic thrombocytopenic purpura.  32:311-318. 2017

Extracorporeal photopheresis practice patterns: An international survey by the ASFA ECP subcommittee.  32:215-223. 2017

“Black cloud” vs. “white cloud” physicians – Myth or reality in apheresis medicine?.  32:235-239. 2017

More apheresis medicine abstracts should be published into manuscripts for clinical use.  32:203-204. 2017

Establishing an institutional therapeutic apheresis registry.  31:516-522. 2016

The thrombotic microangiopathy Registry of North America: A United States multi-institutional TMA network.  31:448-453. 2016

Therapeutic plasma exchange for intractable pruritus secondary to primary sclerosing cholangitis.  31:495-496. 2016

Apheresis research–more abstracts should be published as full manuscripts to provide more evidence for clinical practice guidelines.  31:353-358. 2016

Apheresis in developing countries around the World.  30:238-246. 2015

Therapeutic plasma exchange rapidly improves cardiac allograft function in patients with presumed antibody-mediated rejection.  29:316-321. 2014

Extracorporeal photopheresis: Technique, established and novel indications.  29:228-234. 2014

Out with the bad and in with the good; Red cell exchange, white cell reduction, and platelet reduction.  29:220-227. 2014

Therapeutic apheresis academy 2013: Beyond borders.  29:189-190. 2014

Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research.  29:148-167. 2014

Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab.  28:390-394. 2013

Novel ADAMTS13 mutations in an obstetric patient with Upshaw-Schulman syndrome.  28:311-316. 2013

Update on extracorporeal photopheresis in heart and lung transplantation.  26:146-151. 2011

Guidelines on the use of therapeutic apheresis in clinical practice - Evidence-based approach from the apheresis applications committee of the American Society for Apheresis.  25:83-177. 2010

Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?.  24:209-214. 2009

Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchange.  22:265-269. 2007

Category IV indications for therapeutic apheresis - ASFA fourth special issue.  22:176-180. 2007

Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.  22:106-175. 2007

Photopheresis in solid organ transplant rejection..  21:72-77. 2006

Altering interface detector positioning in combination with prestorage filtration to achieve a better quality of single donor platelet concentrates using the CS 3000 Plus blood separator.  17:21-26. 2002

Characteristics of photopheresis treatments for the management of rejection in heart and lung transplant recipients..  17:27-32. 2002

Patients with thrombotic thrombocytopenic purpura commonly develop metabolic alkalosis during therapeutic plasma exchange.  16:120-124. 2001